Association of serum cortisol and cortisone levels and risk of recurrence after endocrine treatment in breast cancer
Rattachement africain : no, fi. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Metabolic reprogramming in breast cancer involves changes in steroid hormone synthesis and metabolism. Alterations in estrogen levels in both breast tissue and blood may influence carcinogenesis, breast cancer growth, and response to therapy. Our aim was to examine whether serum steroid hormone concentrations could predict the risk of recurrence and treatment-related fatigue in patients with breast cancer. This study included 66 postmenopausal patients with estrogen receptor-positive breast cancer who underwent surgery, radiotherapy, and adjuvant endocrine treatment. Serum samples were collected at six different time points [before the start of radiotherapy (as baseline), immediately after radiotherapy, and then 3, 6, 12 months, and 7–12 years after radiotherapy]. Serum concentrations of eight steroid hormones (cortisol, cortisone, 17α-hydroxyprogesterone, 17β-estradiol, estrone, androstenedione, testosterone, and progesterone) were measured using a liquid chromatography–tandem mass spectrometry-based method. Breast cancer recurrence was defined as clinically proven relapse/metastatic breast cancer or breast cancer-related death. Fatigue was assessed with the QLQ-C30 questionnaire. Serum steroid hormone concentrations measured before and immediately after radiotherapy differed between relapse and relapse-free patients [(accuracy 68.1%, p = 0.02, and 63.2%, p = 0.03, respectively, partial least squares discriminant analysis (PLS-DA)]. Baseline cortisol levels were lower in patients who relapsed than in those who did not (p < 0.05). The Kaplan–Meier analysis showed that patients with high baseline concentrations of cortisol (≥ median) had a significantly lower risk of breast cancer recurrence than patients with low cortisol levels ( p = 0.02). During follow-up, there was a decrease in cortisol and cortisone concentrations in relapse-free patients, whereas these steroid hormones increased in patients who relapsed. In addition, steroid hormone concentrations immediately after radiotherapy were associated with treatment-related fatigue (accuracy of 62.7%, p = 0.03, PLS-DA). However, baseline steroid hormone levels did not predict fatigue at 1 year or at 7–12 years. In conclusion, breast cancer patients with low baseline cortisol levels were more likely to experience recurrence. During follow-up, cortisol and cortisone levels decreased in relapse-free patients but increased in patients with recurrence. Thus, cortisol and cortisone may act as potential biomarkers indicating individual risk of recurrence.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Association of serum cortisol and cortisone levels and risk of recurrence after endocrine treatment in breast cancer
- Date Crossref
- 03/07/2023
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Norwegian University of Science and Technology Department of Circulation and Medical Imaging pays non établi dans la noticeUniversité ou école supérieure
-
St Olav's University Hospital pays non établi dans la noticeÉtablissement de santé
-
Central Norway Regional Health Authority pays non établi dans la noticeOrganisme public
-
University of Oslo pays non établi dans la noticeUniversité ou école supérieure
-
Akershus University Hospital Deparment of Oncology pays non établi dans la noticeÉtablissement de santé
-
Helsinki University Hospital Department of Gynecology pays non établi dans la noticeÉtablissement de santé
-
University of Helsinki Folkhälsan Research Center pays non établi dans la noticeUniversité ou école supérieure
-
Folkhälsans Forskningscentrum pays non établi dans la noticeOrganisme public
-
Trondheim University Hospital Department of Breast and Endocrine Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Clinic of Laboratory Medicine pays non établi dans la noticeStructure de recherche
-
Faculty of Medicine Institute of Clinical Medicine pays non établi dans la noticeUniversité ou école supérieure
Department of Circulation and Medical Imaging — Norwegian University of Science and Technology, St Olav's University Hospital et Central Norway Regional Health Authority, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.